Home › TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA (pembrolizumab) in Solid Tumors
 

Keywords :   


TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA (pembrolizumab) in Solid Tumors

2015-04-20 14:00:00| Merck.com - Product News

Dateline City: MALVERN, Pa. & KENILWORTH, N.J. MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orTetraLogic Investor Relations:Pete A. Meyers, 610-889-9900, x103pete.meyers@tlog.com Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with combination solid evaluation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »